临床荟萃 ›› 2023, Vol. 38 ›› Issue (10): 944-948.doi: 10.3969/j.issn.1004-583X.2023.10.016
杨晓蓉1,2, 周淑红2(
), 潘亮2, 郭莉江1,2
收稿日期:2023-03-22
出版日期:2023-10-20
发布日期:2024-01-03
通讯作者:
周淑红
E-mail:zshlz1973@126.com
Received:2023-03-22
Online:2023-10-20
Published:2024-01-03
摘要：
肺动脉高压作为结缔组织病多系统受累的表现之一,是决定患者预后的重要因素。因其具有发病隐匿、临床表现不典型等特点,需通过多学科综合考量才能达到临床上早期、精准、有效的诊疗目标。本文归纳近年结缔组织病相关肺动脉高压可能的发病机制,为其科学规范达标诊治提供理论指导。
中图分类号:
杨晓蓉, 周淑红, 潘亮, 郭莉江. 结缔组织病相关肺动脉高压的发病机制及其筛查的研究进展[J]. 临床荟萃, 2023, 38(10): 944-948.
| [1] |
Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: Baseline characteristics from the REVEAL Registry[J]. Chest, 2010, 137: 376-387.
doi: 10.1378/chest.09-1140 pmid: 19837821 |
| [2] | 钱君岩, 赵久良, 王迁, 等. 《中国肺动脉高压诊断与治疗指南(2021版)》解读——结缔组织病相关肺动脉高压[J]. 中国实用内科杂志, 2021, 41(12):1030-1034. |
| [3] |
Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: Identifying systemic sclerosis as a unique phenotype[J]. Chest, 2010, 138: 1383-1394.
doi: 10.1378/chest.10-0260 pmid: 20507945 |
| [4] |
Hao YJ, Jiang X, Zhou W, et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients[J]. Eur Respir J, 2014, 44: 963-972.
doi: 10.1183/09031936.00182813 URL |
| [5] | 张晓, 赵久良, 丁峰, 等. 结缔组织病相关肺动脉高压诊疗规范[J]. 中华内科杂志, 2022, 61(11) : 1206-1216. |
| [6] | 樊丽娟, 李闪闪, 王衍, 等. 结缔组织病相关肺动脉高压的临床特点及生存分析[J]. 郑州大学学报:医学版, 2022, 57(5):609-615. |
| [7] |
Zhao J, Wang Q, Liu Y, et al. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China[J]. Int J Cardiol, 2017, 236: 432-437.
doi: S0167-5273(16)34499-0 pmid: 28159359 |
| [8] | 潘婕. 三种结缔组织病相关肺动脉高压的临床特点及预后分析[D]. 南宁: 广西医科大学, 2019. |
| [9] |
van Uden D, Boomars K, Kool M. Dendritic cell subsets and effector function in idiopathic and connective tissue disease-associated pulmonary arterial hypertension[J]. Front Immunol, 2019, 10: 11.
doi: 10.3389/fimmu.2019.00011 pmid: 30723471 |
| [10] |
Pullamsetti SS, Seeger W, Savai R. Classical IL-6 signaling: A promising therapeutic target for pulmonary arterial hypertension[J]. J Clin Invest, 2018, 128: 1720-1723.
doi: 10.1172/JCI120415 pmid: 29629898 |
| [11] |
Wang L, Liu J, Wang W, et al. Targeting IL-17 attenuates hypoxia-induced pulmonary hypertension through downregulation of β-catenin[J]. Thorax, 2019, 74: 564-578.
doi: 10.1136/thoraxjnl-2018-211846 pmid: 30777899 |
| [12] | 张森, 陈延军. 肺动脉高压中炎性反应与免疫反应的发生机制[J]. 医学研究杂志, 2017, 46(4):14-16, 51. |
| [13] |
Li C, Liu PP, Tang DD, et al. Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension[J]. Pulm Pharmacol Ther, 2018, 50: 111-122.
doi: S1094-5539(17)30285-7 pmid: 29673911 |
| [14] | 朱珊英. 免疫功能失调及细胞因子异常与结缔组织相关肺动脉高压的相关性研究[D]. 太原: 山西医科大学, 2020. |
| [15] |
Nicolls MR, Voelkel NF. The Roles of immunity in the prevention and evolution of pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2017, 195: 1292-1299.
doi: 10.1164/rccm.201608-1630PP URL |
| [16] | 李青, 李宏义. 血管外膜成纤维细胞在肺动脉高压中的作用及研究进展[J]. 医学研究杂志, 2020, 49(11):25-28, 32. |
| [17] | 荆志成. 国人肺动脉高压遗传特征及发病机制的探索与应用[D]. 北京: 北京协和医院, 2020. |
| [18] |
Fan Y, Hao YJ, Gao D, et al. Phenotype and function of macrophage polarization in monocrotaline-induced pulmonary arterial hypertension rat model[J]. Physiol Res, 2021, 70: 213-226.
doi: 10.33549/physiolres.934456 pmid: 33676385 |
| [19] |
Tang C, Luo YM, Li S, et al. Characteristics of inflammation process in monocrotaline-induced pulmonary arterial hypertension in rats[J]. Biomed Pharmacother, 2021, 133: 111081.
doi: 10.1016/j.biopha.2020.111081 pmid: 33378977 |
| [20] | 郭迪森, 张榕. 结缔组织病相关肺动脉高压免疫代谢机制的研究进展[J]. 中华风湿病学杂志, 2022, 26(3):205-209. |
| [21] | 孙焕霞, 苏厚恒, 石颜军. 系统性硬化病发病机制探讨及展望[J]. 中华风湿病学杂志, 2020, 24 (7): 491-495. |
| [22] | 李然. 结缔组织病相关肺动脉高压的危险因素及预后分析[D]. 大连: 大连医科大学, 2021. |
| [23] | 汪汉, 何春容. 系统性红斑狼疮相关肺动脉高压的流行病学及发病机制[J]. 心血管病学进展, 2019, 40(4):544-546. |
| [24] |
Minopoulou I, Theodorakopoulou M, Boutou A, et al. Nailfold capillaroscopy in systemic sclerosis patients with and without pulmonary arterial hypertension: A systematic review and meta-analysis[J]. J Clin Med, 2021, 10(7):1528.
doi: 10.3390/jcm10071528 URL |
| [25] |
Donnarumma JFS, Ferreira EVM, Ota-Arakaki J, et al. Nailfold capillaroscopy as a risk factor for pulmonary arterial hypertension in systemic lupus erythematosus patients[J]. Adv Rheumatol, 2019, 59: 1.
doi: 10.1186/s42358-018-0045-5 pmid: 30657102 |
| [26] | 郝俊峰, 陈建建. 从肠道菌群论治肺系疾病[J]. 临床合理用药杂志, 2022, 15(28):177-181. |
| [27] | 于尧, 韩毓梅, 周金哲, 等. 肠道菌群失调与皮肤科常见结缔组织病相关性概述[J]. 中华皮肤科杂志, 2020, 53(4):308-311. |
| [28] |
Brunner K, Samassa F, Sansonetti PJ, et al. Shigella-mediated immunosuppression in the human gut: Subversion extends from innate to adaptive immune responses[J]. Hum Vaccin Immunother, 2019, 15: 1317-1325.
doi: 10.1080/21645515.2019.1594132 URL |
| [29] | 辛晓红, 茹美华, 张升校, 等. 结缔组织病相关肺动脉高压患者肠道菌群分布变化与外周血T淋巴细胞亚群和细胞因子的相关性分析[J]. 中国分子心脏病学杂志, 2021, 21(3):4010-4016. |
| [30] | Zou HX, Qiu BQ, Lai SQ, et al. Iron metabolism and idiopathic pulmonary arterial hypertension: New insights from bioinformatic analysis[J]. Biomed Res Int, 2021, 2021: 1-27. |
| [31] | 禹雪. 肺动脉高压患者氧代谢相关临床研究[D]. 北京: 北京协和医学院, 2019. |
| [32] |
Goyal KK, Saha A, Sahi PK, et al. Hepcidin and proinflammatory markers in children with chronic kidney disease: A case-control study[J]. Clin Nephrol, 2018, 89: 363-370.
doi: 10.5414/CN109132 URL |
| [33] |
Ramakrishnan L, Pedersen SL, Toe QK, et al. Pulmonary arterial hypertension: Iron matters[J]. Front Physiol, 2018, 9: 641.
doi: 10.3389/fphys.2018.00641 pmid: 29904352 |
| [34] | 师悦, 李慕聪, 赵久良, 等. 结缔组织病相关肺动脉高压的遗传学[J]. 中华临床免疫和变态反应杂志, 2020, 14(6):581-586. |
| [35] |
Takagi K, Kawamoto M, Higuchi T, et al. Single nucleotide polymorphisms of the HIF1A gene are associated with susceptibility to pulmonary arterial hypertension in systemic sclerosis and contribute to SSc-PAH disease severity[J]. Int J Rheum Dis, 2020, 23: 674-680.
doi: 10.1111/1756-185X.13822 pmid: 32144871 |
| [36] | Huang C, Yang J, Li MT, et al. CBLN2 rs2217560 was associated with pulmonary arterial hypertension in systemic lupus erythematosus[J]. Chin Med J:Engl, 2018, 131: 3020-3021. |
| [37] | 王婕颖. 原发性干燥综合征相关肺动脉高压的临床队列及生物标志物研究[D]. 北京: 北京协和医学院, 2017. |
| [38] |
Liu Z, Yang X, Tian Z, et al. The prognosis of pulmonary arterial hypertension associated with primary sjögren's syndrome: a cohort study[J]. Lupus, 2018, 27: 1072-1080.
doi: 10.1177/0961203318756287 pmid: 29419347 |
| [39] |
Hu S, Hou Y, Wang Q, et al. Prognostic profile of systemic sclerosis: Analysis of the clinical EUSTAR cohort in China[J]. Arthritis Res Ther, 2018, 20: 235.
doi: 10.1186/s13075-018-1735-4 pmid: 30348207 |
| [40] | 王媛媛, 孙晓萱, 黄颖恒, 等. 血清可溶性生长刺激表达基因2蛋白在结缔组织病相关肺动脉高压中的应用价值[J]. 临床内科杂志, 2020, 37(5):365-367. |
| [41] | 金艳盛, 朱赟, 李伟, 等. 血清25羟基维生素D水平在结缔组织病相关肺动脉高压患者中的临床意义[J]. 中华风湿病学杂志, 2022, 26(2):91-98. |
| [42] | 周持恒, 王钦清. 探讨结缔组织病相关肺动脉高压的临床特点以及临床意义[J]. 实用心脑肺血管病杂志, 2020, 28(S1):101-102. |
| [43] | 苗风楠, 史晓飞, 马新. 结缔组织病继发肺动脉高压的影响因素分析[J]. 河南医学高等专科学校学报, 2021, 33(6):676-680. |
| [44] | 刘娟. 非对称二甲基精氨酸检测对结缔组织病相关肺动脉高压的临床价值[D]. 南昌: 南昌大学, 2019. |
| [45] | 李智腾, 范观止, 段培青, 等. 原发性干燥综合征患者合并肺动脉高压危险因素分析[J]. 中国医科大学学报, 2018, 47(5):420-425. |
| [46] |
Wang J, Li M, Wang Q, et al. Pulmonary arterial hypertension associated with primary sjögren's syndrome: A multicentre cohort study from China[J]. Eur Respir J. 2020, 56(5):1902157.
doi: 10.1183/13993003.02157-2019 URL |
| [47] | 崔祥祥, 杨骥, 屠文震, 等. 130例系统性硬化病患者肺动脉高压的检测及其高危因素分析[J]. 临床皮肤科杂志, 2022, 51(4):204-207. |
| [48] | 朱玲娴, 赵荫环, 张蕊, 等. 系统性硬化症发生肺动脉高压的独立危险因素分析[J]. 风湿病与关节炎, 2023, 12(1):14-18. |
| [49] | 金方圆. 系统性红斑狼疮相关肺动脉高压的临床回顾性分析[D]. 合肥: 安徽医科大学, 2019. |
| [50] |
Wang J, Qian J, Wang Y, et al. Serological biomarkers as risk factors of SLE-associated pulmonary arterial hypertension: A systematic review and meta-analysis[J]. Lupus, 2017, 26: 1390-1400.
doi: 10.1177/0961203317702255 pmid: 28409522 |
| [51] |
Hachulla E, Jais X, Cinquetti G, et al. Pulmonary arterial hypertension associated with systemic lupus erythematosus: Results from the french pulmonary hypertension registry[J]. Chest, 2018, 153: 143-151.
doi: S0012-3692(17)31430-7 pmid: 28851621 |
| [52] | 宋俊梅. 平板运动负荷超声心动图评价结缔组织病右心室收缩功能及其储备[D]. 泸州: 西南医科大学, 2021. |
| [53] | 马红, 周蕾, 王嫱, 等. 二维斑点追踪显像技术评估结缔组织病合并肺动脉高压患者右心室收缩功能的临床研究[J]. 中国循环杂志, 2020, 35(9):910-915. |
| [54] | 宁红霞. 三维超声心动图斑点追踪技术评价结缔组织病相关肺动脉高压患者的心室功能[D]. 沈阳: 中国医科大学, 2018. |
| [55] | 郑丽远, 李扬, 陈巘, 等. 双源CT在诊断结缔组织病肺间质病变致肺动脉高压中的应用[J]. 罕少疾病杂志, 2017, 24(4):3-4, 7. |
| [56] |
Zhang N, Li M, Qian J, et al. Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: Baseline characteristics and risk factors[J]. Int J Rheum Dis, 2019, 22(5): 921-928.
doi: 10.1111/1756-185X.13478 pmid: 30746850 |
| [57] |
Huang C, Li M, Liu Y, et al. Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients[J]. Medicine, 2016, 95(10): e2761.
doi: 10.1097/MD.0000000000002761 URL |
| [58] | Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Rev Esp Cardiol(Engl Ed), 2016, 69(2): 177. |
| [59] |
Young A, Nagaraja V, Basilious M, et al. Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension[J]. Semin Arthritis Rheum, 2019, 48(6): 1059-1067.
doi: 10.1016/j.semarthrit.2018.10.010 URL |
| [60] |
Yan S, Li M, Wang H, et al. Characteristics and risk factors of pulmonary arterial hypertension in patients with primary Sjogren's syndrome[J]. Int J Rheum Dis, 2018, 21(5): 1068-1075.
doi: 10.1111/apl.2018.21.issue-5 URL |
| [1] | 左腾, 王俊祥. 血清阴性类风湿关节炎发病机制的研究进展[J]. 临床荟萃, 2023, 38(8): 753-756. |
| [2] | 贾丽娜, 吴美妮, 尹昌浩. 2型糖尿病认知功能障碍发病机制的研究进展[J]. 临床荟萃, 2023, 38(6): 554-558. |
| [3] | 邹琳, 崔轶霞, 张娜娜, 陈思荣. 类风湿关节炎合并骨质疏松症发病机制和相关治疗药物对骨质疏松症影响的研究进展[J]. 临床荟萃, 2023, 38(3): 279-284. |
| [4] | 彭艳, 白碧玥, 朱晓峰, 尹昌浩. 酒精使用障碍患者认知功能损害发病机制的研究进展[J]. 临床荟萃, 2023, 38(12): 1131-1134. |
| [5] | 曾晓晴, 庄伟端, 陈丽芬. 卒中后癫痫发作发病机制的研究进展[J]. 临床荟萃, 2022, 37(2): 174-177. |
| [6] | 张慧卿，路延朋，宋学琴. CAPN3基因突变导致的Calpainopathy的发病机制、临床表现和实验室检测研究进展[J]. 临床荟萃, 2020, 35(6): 564-567. |
| [7] | 李晶雪，李哲，王天俊. 帕金森病伴发抑郁发病机制及治疗的研究进展[J]. 临床荟萃, 2019, 34(8): 759-763. |
| [8] | 李晶雪，王天俊. 卒中后抑郁发病机制及治疗研究进展[J]. 临床荟萃, 2019, 34(6): 572-576. |
| [9] | 冯三丽1, 2，张静楠2，乔淑凯2，王文飞1，李扬2，邢丽娜2，郭晓楠2. 原发性骨髓纤维化伴阵发性睡眠性血红蛋白尿1例并文献复习[J]. 临床荟萃, 2019, 34(12): 1119-1122. |
| [10] | 安苗a, 杨林b, 武柏林a. 结缔组织病伴发淋巴结肿大的影像、病理特征及临床意义[J]. 临床荟萃, 2018, 33(9): 817-820. |
| [11] | 高红梅，唐亚，王俭勤. 糖尿病肾病分子遗传学发病机制的研究进展[J]. 临床荟萃, 2018, 33(3): 271-276. |
| [12] | 张光明，崔炜. 重新认识冠状动脉痉挛[J]. 临床荟萃, 2018, 33(10): 907-913. |
| [13] | 高燕1， 李林倩2， 王倩2，张思2，张海松1. 肝细胞因子在糖尿病肾病发病中的作用[J]. 临床荟萃, 2018, 33(10): 859-862. |
| [14] | 黄慕芳，杨敏，于奕奕. 结缔组织病合并马尔尼菲青霉菌病1例并文献复习[J]. 临床荟萃, 2017, 32(6): 531-535. |
| [15] | 张洋洋, 袁雅冬. 羊水栓塞的诊治[J]. 临床荟萃, 2016, 31(4): 368-372. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
